Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement
Evolving Treatment Strategies for Chronic Lymphocytic Leukemia: Insights From Experts Across Mayo Clinic Locations : Episode 2

Navigating 1L Treatment Selection with BTKis in CLL

January 11, 2024
By Sameer A. Parikh, MD
Sikander Ailawadhi, MD
  • Mazie Tsang, MD, MAS, MS
  • Amber Koehler, PA-C, MS

Opinion
Video

Expert faculty discuss consideration factors in guiding frontline treatment selection with BTKis in CLL.

CN_ATP_CLL_MAYO_Seg03
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      EP: 1.Evolving Front-line Treatment Options for CLL

      Now Viewing

      EP: 2.Navigating 1L Treatment Selection with BTKis in CLL

      EP: 3.Updates on BTKi Monotherapy for CLL in the Frontline Setting

      EP: 4.The Role of BTKi + Obinutuzumab for 1L Treatment of CLL

      EP: 5.Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

      EP: 6.Updates on Combination Treatment Approaches with BTKi + Venetoclax

      EP: 7.Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting

      EP: 8.Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR

      EP: 9.Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

      EP: 10.Key Considerations in Managing Hypertension Risk with BTKis in CLL

      EP: 11.Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL

      EP: 12.Managing Bleeding Risk in Patients with CLL on BTKi Therapy

      EP: 13.Utilizing Real-World Data for Informed Decision-Making in CLL

      EP: 14.Navigating Treatment Resistance and Sequencing in CLL

      EP: 15.Advancements with Novel Treatment Approaches in CLL

      EP: 16.Future Perspectives and Unmet Needs in CLL

      Recent Videos
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      Related Content
      Advertisement
      3 Things You Should Know About Advances in CLL Management

      3 Things You Should Know About Advances in CLL Management

      ONCOLOGY Staff
      May 20th 2025
      Article

      Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      Tim Cortese
      May 6th 2025
      Article

      The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      Tim Cortese
      April 30th 2025
      Article

      Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

      Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

      Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

      Roman Fabbricatore
      April 25th 2025
      Article

      Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

      Related Content
      Leukemia
      |
      Hematologic Oncology
      |
      Evolving Treatment Strategies for Chronic Lymphocytic Leukemia: Insights From Experts Across Mayo Clinic Locations
      Advertisement
      3 Things You Should Know About Advances in CLL Management

      3 Things You Should Know About Advances in CLL Management

      ONCOLOGY Staff
      May 20th 2025
      Article

      Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

      Tim Cortese
      May 6th 2025
      Article

      The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      Tim Cortese
      April 30th 2025
      Article

      Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

      Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

      Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

      Roman Fabbricatore
      April 25th 2025
      Article

      Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

      Advertisement
      Advertisement
      Advertisement
      Advertisement
      x
      About
      Advertise
      CureToday.com
      OncLive.com
      OncNursingNews.com
      TargetedOnc.com
      Editorial
      Contact
      Terms and Conditions
      Privacy
      Do Not Sell My Personal Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.